#United States #New York #Lucid Diagnostics #PAVmed #Veris Health

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

On August 14, 2026, PAVmed Inc. (NASDAQ: PAVM), a diversified commercial-stage medical technology enterprise, shared its business progress alongside its financial results for the second quarter that ended on June 30, 2026. The company operates within the medical device, diagnostics, and digital health sectors, showcasing robust advancements across its subsidiaries — Lucid Diagnostics Inc., Veris Health Inc., and Octeris Medical Inc.

Conference Call Details

For investors and stakeholders, PAVmed will be hosting a conference call and a webcast at 8:30 AM EDT on August 14, 2026. To join the call by phone, U.S. callers can dial 1-800-836-8184 while international listeners can reach the conference by calling 1-646-357-8785. For online participation, the webcast is available in the investor relations section of PAVmed's website, pavmed.com. Following the event, a replay will be accessible for 30 days, allowing those who miss the live session to catch up on the developments.

Business Highlights

Lishan Aklog, M.D., Chairman and CEO of PAVmed, expressed optimism regarding the company's trajectory, stating that there were tangible milestones achieved in various core businesses throughout the past quarter. He emphasized the advancement of Veris Health in its collaboration with OSU-The James and the progress of the implantable physiological monitor, with plans for an early 2027 FDA submission.

Lucid Diagnostics has made noteworthy strides, securing a significant laboratory benefit manager coverage policy for the EsoGuard test. This direct affirmation of the test's medical necessity aligns with ongoing efforts to enhance revenue streams, as the company noted $1.5 million in EsoGuard revenue for the second quarter, alongside the processing of 2,770 EsoGuard tests.

Additionally, PAVmed is revitalizing its medical device portfolio, particularly with PortIO and Octeris, as they journey toward critical development milestones.

Subsidiary Achievements

• - Veris Health: The company is experiencing accelerated patient onboarding at OSU-The James, expanding clinical operations across various departments. As part of their commitment to innovation, Veris is nearing the completion of the design freeze and preliminary verification for the implantable physiological monitor, gearing up for its FDA submission in 2027.

• - Lucid Diagnostics: This segment is witnessing a surge in usage of the EsoGuard test, alongside the establishment of the first laboratory benefit manager coverage policy, enhancing its market presence significantly.

Medical Device Portfolio Developments

PAVmed's medical device segment, including PortIO, presented first-in-human results that were recently published, revealing a 100% device patency and demonstrating high performance with no reported adverse events. Moreover, Octeris continues to refine its multimodal endoscopic imaging probe, improving both its form factor and processing capabilities ahead of clinical validation studies slated for the University of North Carolina.

Financial Overview

For Q2 2026, PAVmed reported approximately $7.1 million in operational expenses, including $0.9 million attributed to stock-based compensation. The company recorded a GAAP net loss of $5.5 million, translating to $(0.87) per diluted share. However, adjusting for stock-based compensation and non-cash expenses yielded a non-GAAP adjusted net loss of approximately $1.7 million, or $(0.27) per share.

The company noted a positive cash position, reporting $3.8 million as of June 30, 2026, a substantial increase compared to $1.5 million at the end of 2025.

Looking Ahead

PAVmed continues to emphasize transparency by disclosing non-GAAP measures to provide a clearer picture of operational performance. These metrics help stakeholders assess ongoing performance and draw comparisons to historical financial results. The company remains committed to advancing its innovative products and improving healthcare solutions globally.

Through strategic partnerships and a focus on core strengths in medical technology, PAVmed is steering toward a promising future. Investors are encouraged to stay updated via their investor relations portal and remain vigilant about upcoming announcements, focusing on continual learning and adaptation in the ever-evolving health tech landscape.

For more information about PAVmed and its subsidiaries, please visit pavmed.com, luciddx.com, and verishealth.com.